{"id":"liposome-encapsulated-daunorubicin-cytarabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1200475","moleculeType":"Small molecule","molecularWeight":"719.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daunorubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation, while cytarabine is a nucleoside analog that inhibits DNA polymerase and gets incorporated into DNA, causing chain termination. Encapsulation in liposomes enhances cellular uptake and reduces systemic toxicity by preferentially targeting leukemic blasts.","oneSentence":"A liposome-encapsulated combination of two chemotherapy drugs (daunorubicin and cytarabine) that delivers cytotoxic agents directly into leukemic cells to inhibit DNA synthesis and induce cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:03.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) in elderly or unfit patients"},{"name":"Relapsed or refractory acute leukemia"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT02286726","phase":"PHASE2","title":"CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT03896269","phase":"PHASE1","title":"CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-14","conditions":"Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia","enrollment":38},{"nctId":"NCT03629171","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-29","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT03672539","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-11-07","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT04915612","phase":"PHASE1","title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-21","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT04269213","phase":"PHASE2","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2021-07-29","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT04802161","phase":"PHASE2","title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia","enrollment":50},{"nctId":"NCT04128748","phase":"PHASE1, PHASE2","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-27","conditions":"Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT04493164","phase":"PHASE2","title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-30","conditions":"Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":30},{"nctId":"NCT03878199","phase":"PHASE1, PHASE2","title":"Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2019-02-20","conditions":"Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm","enrollment":12},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT03844997","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sudipto Mukherjee, MD, PhD, MPH","startDate":"2019-06-06","conditions":"Acute Myeloid Leukemia, AML","enrollment":35},{"nctId":"NCT04049539","phase":"PHASE1, PHASE2","title":"Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-01-29","conditions":"Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT04526288","phase":"PHASE2","title":"CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-08-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm","enrollment":1},{"nctId":"NCT06182592","phase":"PHASE3","title":"A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-01","conditions":"High-risk (Secondary) Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT03904251","phase":"PHASE1","title":"CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-07-18","conditions":"Acute Myelogenous Leukemia","enrollment":13},{"nctId":"NCT03825796","phase":"PHASE2","title":"CPX-351 Plus Enasidenib for Relapsed AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-12","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT05801835","phase":"NA","title":"A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection","status":"UNKNOWN","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-08-25","conditions":"Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT02642965","phase":"PHASE1, PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2016-05-02","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":38},{"nctId":"NCT05320380","phase":"PHASE1, PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia","enrollment":""},{"nctId":"NCT03760445","phase":"PHASE1, PHASE2","title":"HDM201 Added to CT in R/R or Newly Diagnosed AML","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2019-11-15","conditions":"Leukemia, Myeloid, Acute","enrollment":""},{"nctId":"NCT02019069","phase":"PHASE2","title":"CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Rondeep Brar","startDate":"2014-02-03","conditions":"Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":11},{"nctId":"NCT01804101","phase":"NA","title":"Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-05-07","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":48},{"nctId":"NCT02269579","phase":"PHASE2","title":"Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2015-04","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CPX-351","Cytarabine-Daunorubicin Liposome for Injection","Liposomal Cytarabine (AraC)-Daunorubicin CPX-351","Liposomal Cytarabine-Daunorubicin","Liposome-encapsulated Combination of Daunorubicin and Cytarabine"],"phase":"phase_3","status":"active","brandName":"Liposome-encapsulated Daunorubicin-Cytarabine","genericName":"Liposome-encapsulated Daunorubicin-Cytarabine","companyName":"Fred Hutchinson Cancer Center","companyId":"fred-hutchinson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A liposome-encapsulated combination of two chemotherapy drugs (daunorubicin and cytarabine) that delivers cytotoxic agents directly into leukemic cells to inhibit DNA synthesis and induce cell death. Used for Acute myeloid leukemia (AML) in elderly or unfit patients, Relapsed or refractory acute leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":18,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}